Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 millionReports preliminary full-year 2024 ...

Lake Street analyst Frank Takkinen reiterated a Buy rating on Iradimed (IRMD – Research Report) today and set a price target of $60.00. The ...

With more than 325,000 pumps installed worldwide, the Plum A+™ general purpose infusion system remains ... Deliver secondary infusions via IV container or syringe ...

Harsoria said it will use the funding to expand its manufacturing capabilities, improve research and development (R&D) ...

Baxter is still recovering from the temporary shutdown of its intravenous and peritoneal fluid manufacturing plant in Marion, ...

Elevated patient expectations and sizable geriatric cohorts boost device advancements, from neuromodulators to remote ...

Although, preclinical data suggest that the behavioral expression of opioid use is similar between male and female rodents, we do not have conclusive results on sex differences on craving and relapse ...

10, 2024 — In a single IV injection, a gene therapy targeting ... AI-ECG tools identified more unknown cases of a weak heart pump, also called low ejection fraction, than without AI.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...